Patients living with rare neuromuscular diseases face some of the longest diagnostic journeys in medicine, often spending years in a system that cannot yet recognise what is happening to them. On 15 October 2026, Volv Global founder and CEO Christopher Rudolf joins the DREAMS Project for the webinar “Artificial Intelligence for Rare Neuromuscular Diseases: From Early Diagnosis to Drug Discovery and Clinical Translation” – alongside Dr. GoHun Seo of 3billion and Dr. Rubal Ravinder of Kantify – to explore what machine learning can achieve across three distinct but interconnected challenges: identifying patients through genetic screening, discovering drugs for difficult targets, and surfacing the patients that population-scale real-world data can reveal. Together, the three speakers address the full arc the webinar’s title describes.
For patients with rare neuromuscular diseases, earlier recognition and faster access to the right care are achievable.
The science is ready. What matters now is how it is deployed.
Our founder and CEO, Christopher Rudolf, will present Volv Global’s machine learning work on Pompe disease as a concrete case study in what population-scale real-world data can achieve for patients with rare and difficult-to-diagnose conditions. Starting from real-world endpoint mapping and the identification of evolving Pompe disease phenotypes, he will show how the methodology surfaces patients who have been missed by conventional coding and keyword-based search, how it detects phenotypic change ahead of standard clinical recognition, and what the implications are for pharmaceutical teams working across the rare neuromuscular disease landscape.
The lessons Christopher draws from Pompe disease extend directly to the neuromuscular disease field more broadly. Volv Global’s machine learning methodology is designed to adapt across disease areas and healthcare systems, overcoming the data fragmentation, coding variability, and systemic bias that make rare diseases so hard to study in the real world. For pharmaceutical teams in clinical development, HEOR, medical affairs, and commercial excellence, the Pompe case study illustrates what becomes achievable when rigorous data science is applied to the right questions: patients found earlier, phenotypic diversity understood, and clinical evidence built on a firmer evidential foundation.
With more than two decades at the intersection of data science, clinical systems, and real-world healthcare, Christopher brings a perspective shaped by what happens when methodology meets genuine clinical need. He will speak to what it takes to make machine learning work reliably at the population level in rare disease, and why the results produced in one condition can be reproduced across others – including the neuromuscular diseases at the centre of the DREAMS Project’s mission.
For those working in clinical development, medical affairs, HEOR, and commercial excellence in rare disease, this webinar offers a direct view of where AI can deliver clear value. Dr. Gohun Seo, Chief Medical Officer of 3billion, presents on AI-powered genetic screening for early identification of potential neuromuscular disorders. Dr. Rubal Ravinder, Machine Learning Engineer at Kantify, addresses machine learning for target and drug discovery in the same disease area. Christopher brings the third layer: population-scale real-world data and what it reveals about patients already in the system. The session closes with a panel discussion and live Q&A moderated by François Lamy, Vice-President of AFM-Téléthon.
The DREAMS Project is a Horizon Europe initiative focused on harnessing artificial intelligence for drug discovery and clinical translation in rare neuromuscular disorders. Bringing together researchers, clinicians, technology providers, and patient advocates, the project reflects the kind of multi-stakeholder collaboration required to move the field forward. Volv Global’s participation reflects a shared commitment: ensuring that patients with rare neuromuscular diseases are identified, supported, and reached by the science being developed on their behalf.
To find out more about Volv Global’s work in rare and difficult-to-diagnose neuromuscular disease, or to arrange a conversation with the team, please contact us.
About the webinar
- DREAMS Project Webinar: Artificial Intelligence for Rare Neuromuscular Diseases
- 15 October 2026 | 10:00–11:15 CEST
- Online via Microsoft Teams
- Moderator: François Lamy, Vice-President, AFM-Téléthon
- Register here.
Speakers
- Dr Gohun Seo, Chief Medical Officer, 3billion – “Early screening to identify potential neuromuscular disorders”
- Dr Rubal Ravinder, Machine Learning Engineer, Kantify – “Machine Learning for target and drug discovery in rare neuromuscular diseases”
- Christopher Rudolf, Founder and CEO, Volv Global – “Real-world endpoint mapping and identification of evolving Pompe disease phenotypes using Machine Learning”
Key Takeaways
- Christopher Rudolf, Volv Global CEO, presents at the DREAMS Project AI webinar on 15 October 2026.
- His presentation draws on Volv Global’s machine learning work in Pompe disease – real-world endpoint mapping and evolving phenotype identification – as a case study with implications across rare neuromuscular disease.
- The three speakers address three complementary layers of AI in this disease area: genetic screening for early identification (3billion), machine learning for drug and target discovery (Kantify), and population-scale real-world data for patient finding and care pathway insight (Volv Global).
- Volv Global draws on real-world data covering more than 400 million patients to surface patients who are undiagnosed, support earlier detection, and identify eligible patients not yet receiving available therapies.
- The DREAMS Project is a Horizon Europe initiative bringing together AI, clinical, and research expertise to accelerate drug discovery and clinical translation in rare neuromuscular disorders.
Links
- inTrigue – Finding patients
- inAdvance – Finding patients earlier
-
Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data
Frequently Asked Questions
Q1: What is the DREAMS Project?
DREAMS is a Horizon Europe initiative focused on artificial intelligence for drug discovery and clinical translation in rare neuromuscular disorders. The project brings together researchers, clinicians, technology companies, and patient advocates to accelerate progress for patients in this disease area. AFM-Téléthon is among its partners.
Q2: What will Christopher Rudolf present at the webinar?
Christopher will present Volv Global’s machine learning work on Pompe disease – specifically real-world endpoint mapping and the identification of evolving disease phenotypes. He will draw out the broader implications of this work for the rare neuromuscular disease field: how population-scale real-world data can surface patients who are currently missed, support earlier recognition, and provide a firmer evidential foundation for pharmaceutical development and clinical decision-making.
Q3: Who else is speaking at the DREAMS webinar?
Dr Gohun Seo, Chief Medical Officer of 3billion, presents on AI-powered genetic screening for early identification of potential neuromuscular disorders. Dr Rubal Ravinder, Machine Learning Engineer at Kantify, addresses machine learning for target and drug discovery in rare neuromuscular diseases. Together the three speakers address the full arc from drug discovery to patient identification and care. The session is moderated by François Lamy, Vice-President of AFM-Téléthon.
Q4: Who should attend?
The webinar is directly relevant to those working in clinical development, HEOR, value and access, medical affairs, and commercial excellence within pharmaceutical and biotech companies focused on neuromuscular disease. Researchers, clinicians, and patient advocates with an interest in AI applications in this disease area will also find it valuable.
Q5: How does Volv Global’s approach apply to neuromuscular disease more broadly?
Volv Global’s machine learning methodology is designed to adapt across disease areas and healthcare systems. The work in Pompe disease demonstrates a methodology that can be applied to other rare neuromuscular conditions: surfacing patients not captured by standard coding, identifying phenotypic variation within a disease population, and mapping real-world endpoints that inform both clinical development and care pathway design.
